Refine
Document Type
- Article (21)
- Preprint (2)
- Contribution to a Periodical (1)
Has Fulltext
- yes (24)
Is part of the Bibliography
- no (24)
Keywords
- SARS-CoV-2 (4)
- COVID-19 (2)
- microbiome (2)
- AML (1)
- Antibiotics (1)
- Antiretroviral therapy (1)
- B.1.617.1 (1)
- B.1.617.2 (1)
- BNT2b2 (1)
- Bacteria (1)
- Bloodstream infection (1)
- CDI (1)
- CRP (1)
- Cancer (1)
- Catheters (1)
- Clostridioides difficile (1)
- Cluster (1)
- Colonisation (1)
- Contact precautions (1)
- D-dimer (1)
- DST (1)
- Drug susceptibility testing (1)
- Epsilon (1)
- Gene sequencing (1)
- Gut bacteria (1)
- HIV (1)
- Hematology (1)
- Induction chemotherapy (1)
- Infection control (1)
- Influenza (1)
- Kappa (1)
- M. Intracellulare (1)
- M. avium (1)
- M. avium complex (1)
- M. chimaera (1)
- Microbiome (1)
- Multidrug-resistant bacteria (1)
- Mycobacteria (1)
- Mycobacterium avium complex (1)
- NAFL (1)
- NASH (1)
- NTM (1)
- Non-tuberculous mycobacteria (1)
- Nontuberculous mycobacteria (1)
- Oncology (1)
- Opportunistic infections (1)
- Parainfluenza (1)
- Pneumonia (1)
- Protease inhibitor therapy (1)
- Respiratory infections (1)
- Respiratory syncytial virus (1)
- Ribosomal RNA (1)
- Superinfection (1)
- Upper respiratory tract infection (1)
- Urine (1)
- acute-on-chronic liver failure (1)
- ascites (1)
- bacteriophages (1)
- cirrhosis (1)
- comorbidities (1)
- corona virus (1)
- critically ill patients (1)
- cytokines (1)
- delta (1)
- diagnostic algorithm (1)
- dysbiosis (1)
- faecal microbiota transfer (1)
- fecal microbiota transfer (1)
- fidaxomicin (1)
- graft-vs-host disease (1)
- gut microbiota (1)
- human allogeneic hematopoietic cell transplantation (1)
- human intestinal microbiota (1)
- infection (1)
- lasso regression (1)
- lung disease (1)
- mRNA1273 (1)
- miRNA (1)
- monoclonal antibodies (1)
- myeloid cells (1)
- neurological manifestations (1)
- nomogram (1)
- preventive strategies (1)
- recurrent urinary tract infections (1)
- respiratory failure (1)
- risk factors (1)
- systemic inflammation (1)
- vaccination (1)
- vancomycin (1)
The capacity of convalescent and vaccine-elicited sera and monoclonal antibodies (mAb) to neutralize SARS-CoV-2 variants is currently of high relevance to assess the protection against infections.
We performed a cell culture-based neutralization assay focusing on authentic SARS-CoV-2 variants B.1.617.1 (Kappa), B.1.617.2 (Delta), B.1.427/B.1.429 (Epsilon), all harboring the spike substitution L452R.
We found that authentic SARS-CoV-2 variants harboring L452R had reduced susceptibility to convalescent and vaccine-elicited sera and mAbs. Compared to B.1, Kappa and Delta showed a reduced neutralization by convalescent sera by a factor of 8.00 and 5.33, respectively, which constitutes a 2-fold greater reduction when compared to Epsilon. BNT2b2 and mRNA1273 vaccine-elicited sera were less effective against Kappa, Delta, and Epsilon compared to B.1. No difference was observed between Kappa and Delta towards vaccine-elicited sera, whereas convalescent sera were 1.5-fold less effective against Delta, respectively. Both B.1.617 variants Kappa (+E484Q) and Delta (+T478K) were less susceptible to either casirivimab or imdevimab.
In conclusion, in contrast to the parallel circulating Kappa variant, the neutralization efficiency of convalescent and vaccine-elicited sera against Delta was moderately reduced. Delta was resistant to imdevimab, which however, might be circumvented by a combination therapy with casirivimab together.
Background and Aim: Several studies observed alterations in the gut microbiota in patients with non‐alcoholic fatty liver disease (NAFLD). However, analyzed patient populations and methods strongly differ among these studies. The aim of this study was to prove the reproducibility of published results and to provide a detailed overview of all findings in our NAFLD cohort using next generation sequencing methods.
Methods: The individual taxonomic microbiota composition of fecal samples from 90 NAFLD patients and 21 healthy controls was analyzed using 16S rRNA gene sequencing. Study participants were grouped according to their disease stage and compared regarding their gut microbiota composition. Studies were identified from PubMed listed publications, and the results were compared with the findings in our cohort.
Results: Results from 13 identified studies were compared with our data. A decreased abundance of the Bacteroidetes and Ruminococcaceae as well as an increased abundance of Lactobacillaceae and Veillonellaceae and Dorea were the most frequently reported changes among NAFLD patients in 4/13, 5/13, 4/13, 2/13, and 3/13 studies, respectively. Even though these alterations in the gut microbiota composition were also observed in our patient cohort, the majority of published differences could not be reproduced, neither in our own nor in other NAFLD cohort studies.
Conclusion: Despite repeatedly reproduced abundance patterns of specific bacteria, the heterogeneous study results did not reveal a consistent disease specific gut microbiota signature. Further prospective studies with homogenous patient cohorts and standardized methods are necessary to phenotype NAFLD by the gut microbiota.
Overconsumption of carbohydrates and lipids are well known to cause nonalcoholic fatty liver disease (NAFLD), while the role of nutritional protein intake is less clear. In Western diet, meat and other animal products are the main protein source, with varying concentrations of specific amino acids. Whether the amount or composition of protein intake is associated with a higher risk for disease severity has not yet been examined. In this study, we investigated associations of dietary components with histological disease activity by analyzing detailed 14‐day food records in a cohort of 61 patients with biopsy‐proven NAFLD. Furthermore, we used 16S ribosomal RNA gene sequencing to detect associations with different abundances of the gut microbiota with dietary patterns. Patients with definite nonalcoholic steatohepatitis (NAFLD activity score of 5‐8 on liver biopsy) had a significantly higher daily relative intake of protein compared with patients with a NAFLD activity score of 0‐4 (18.0% vs. 15.8% of daily protein‐based calories, P = 0.018). After adjustment for several potentially confounding factors, a higher protein intake (≥17.3% of daily protein‐based calories) remained associated with definite nonalcoholic steatohepatitis, with an odds ratio of 5.09 (95% confidence interval 1.22‐21.25, P = 0.026). This association was driven primarily by serine, glycine, arginine, proline, phenylalanine, and methionine. A higher protein intake correlated with a lower Bacteroides abundance and an altered abundance of several other bacterial taxa. Conclusion: A high protein intake was independently associated with more active and severe histological disease activity in patients with NAFLD. Further studies are needed to investigate the potential harmful role of dietary amino acids on NAFLD, with special attention to meat as their major source.
The combination of pamapimod and pioglitazone (KIN001) has a synergetic antiviral, anti-inflammatory, and antifibrotic activity, which may prevent evolution toward COVID-19-associated severe respiratory failure. In a randomized, placebo-controlled, double-blind, phase 2, multicenter trial, 128 non-critically ill hospitalized patients with confirmed COVID-19 were treated with KIN001 or a placebo for 28 days. The proportion of patients alive and free of oxygen or respiratory support at the end of the therapy was lower than anticipated but not different in the two groups (KIN001 n = 19, 29%, placebo n = 21, 33%). 85 participants had at least one adverse event, with no difference in the number and distribution of events between the two groups. The clinical trial was stopped for futility, mainly due to a lower-than-expected incidence of the primary endpoint. KIN001 was safe and well-tolerated but had no significant effect on clinical outcome.